Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Learn which cards offer bonus rewards without any annual fees. Start enjoying rewards without the financial burden.
25,653 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
When a stock beats estimates but slides after hours, it creates a nagging question for investors. Here’s a clear, pra...
A lithium-extraction startup says its new method triples recovery while shortening timelines, accelerating toward com...
Retirees are increasingly turning to the iShares MSCI Pacific ex-Japan ETF to secure dividend cash from Australia, Ho...
A practical guide to interpreting Champions Oncology earnings. We break down the numbers, trends, and what to watch n...
Henry Hub natural gas vaulted to $7.72 in January before tumbling to $3.62 in February, forcing traders to pick sides...
IonQ just posted revenue that more than tripled for the third straight quarter, but the stock sold off despite the ga...
Pershing Square signals a bold bet by leaning into Microsoft as the AI and cloud wave reshapes enterprise tech. The m...
JPMorgan argues a bold AI productivity push—the moonshot to avoid trillion national debt—could avert a looming $39 tr...
ASML stock rose in May as demand for EUV technology and a healthier semiconductor cycle supported the rally. This gui...
Celebrity stories can hide practical money lessons. This piece breaks down what we can learn from the way Jerry Hall ...
A wide-reaching benefits-fraud crackdown in Massachusetts resulted in 15 charges for schemes totaling more than $1.4 ...